A new report by the ratings agency Fitch says brand name drugs will increase their revenues by a modest 2-3% in 2014. They also note that this is still one of the highest-rated industries. According to Fitch, patent expiries next year will take about $34 B of branded sales from the market as compared to $28 B in 2013 and $55 B in 2012.
Despite this, and the fact that FDA has approved only 24 NDAs this year compared with 39 last year, the agency still predicts that the last two year's cohorts will be able to help fuel overall growth. Cost cutting will still be popular though to manage the botom line, and companies will still divest underperforming non-core assets. Duh? See PharmaTimes.
Posted by Bruce Lehr Dec 17th 2013.